Metabolic changes during successful medical therapy for brain hydatid cyst: case report.
BACKGROUND
Medical therapy for hydatid disease of the brain has been reported with encouraging results especially in small or medium-sized cysts. To date, no other case correlating the metabolite levels of the cyst with albendazole treatment has been reported.


METHODS
A 52-year-old woman presented with left hemiparesis and seizure. Cranial magnetic resonance revealed a right frontal cystic mass lesion. A diagnosis of hydatid cyst was made, and she was put on medical therapy with albendazole. An MRS before the medical therapy was begun revealed the typical findings of a hydatid cyst with resonance of alanine, acetate, and succinate that were specific for hydatid disease, and additional nonspecific lactate peaks with an additional small peak of choline. Comparison between the multiple MRS examinations was made by comparing the metabolite ratios specific for hydatid disease to choline, which seemed stable from the beginning. Two sequential MRS imaging revealed a prominent decrease of the succinate and acetate resonance, accompanied by a smaller decline of the alanine resonance progressively, correlated with the conventional MRI findings of the cyst, which had a smaller size with blurred margins in the meantime. After 5 months of medical treatment, the cyst had completely disappeared. The patient has been monitored for 5 years and remains well without recurrence.


CONCLUSIONS
This case provides additional proof that the brain hydatid cyst is a medically treatable disease in appropriate cases. Furthermore, the changes in the metabolic profile of the cyst, especially those regarding succinate and acetate may represent the efficacy of the medical treatment.
Seckin
Hakan
H
Ministry of Health, Ankara Diskapi Training and Research Hospital, 2nd Neurosurgery Clinic, Ankara, Turkey.
Yagmurlu
Banu
B
Yigitkanli
Kazim
K
Kars
H Zafer
HZ
D019342:Acetic Acid / Q000032:analysis / Q000378:metabolism; D000409:Alanine / Q000032:analysis / Q000378:metabolism; D015766:Albendazole / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000923:Anticestodal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism* / Q000469:parasitology* / Q000473:pathology; D004443:Echinococcosis / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D004446:Echinococcus / Q000187:drug effects; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D019802:Succinic Acid / Q000032:analysis / Q000378:metabolism; D016896:Treatment Outcome
D000923:Anticestodal Agents; D019802:Succinic Acid; D015766:Albendazole; D000409:Alanine; D019342:Acetic Acid